Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.

Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.

Abstract: A motion platform for use with a video simulation system is described. The platform is configured to provide simultaneous roll-axis and yaw-axis motion about a pivot point for simulating a aircraft environment. Additionally, the motion platform is configured to achieve motion using a single linear actuator, and thus is provided at a significantly reduced cost compared to conventional motion platforms. Other benefits of the motion platform include improved power efficiency, reduced weight for increased portability, and reduced maintenance due to only one linear actuator driving the system.

Abstract: A motion platform for use with a video simulation system is described. The platform is configured to provide simultaneous roll-axis and yaw-axis motion about a pivot point for simulating a aircraft environment. Additionally, the motion platform is configured to achieve motion using a single linear actuator, and thus is provided at a significantly reduced cost compared to conventional motion platforms. Other benefits of the motion platform include improved power efficiency, reduced weight for increased portability, and reduced maintenance due to only one linear actuator driving the system.

Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.

Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.

Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.

Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.

Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.

Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.

Abstract: A trailer brake system includes a full power hydraulic brake system that is electrically controlled by a system control unit. The trailer brake system includes a power unit that maintains a pressurized supply of hydraulic fluid and a brake control unit that is fluidly connected between the power unit and trailer wheel brake components. The power unit includes an electric motor driven pump and accumulator that is in fluid communication with a trailer supply reservoir. The brake control unit includes an inlet valve that is fluidly connected to the accumulator and an outlet valve that is fluidly connected to the trailer supply reservoir. The system control unit generates control signals to the power unit and brake control unit to respectively maintain a desired pressure level in the accumulator, and to apply the trailer wheel brake components through the brake control unit.

Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.

Abstract: A method of inhibiting or reducing the irritation of skin resulting from allergic contact dermatitis, caused by contact with natural or synthetic allergenic agents, e.g. poison ivy, and dinitrochlorobenzene, respectively, is described. The method comprises applying to the skin an irritating reducing effective amount of a protective agent which is an organic compound having at least two polar groups, e.g. carboxyl groups, separated by a chain of at least 15 atoms the majority of which are carbon atoms and optionally containing a cyclic moiety of at least 5 atoms, prior to contact of the skin with the allergenic agent. The protective agent may be combined in a pharmacologically acceptable base for application to the skin.

Abstract: A method of inhibiting or reducing the irritation of skin resulting from allergic contact dermatitis, caused by contact with natural or synthetic allergenic agents, e. g. poison ivy, and dinitrochlorobenzene, respectively, is described. The method comprises applying to the skin an irritating reducing effective amount of a protective agent which is an organic compound having at least two polar groups, e.g. carboxyl groups, separated by a chain of at least 15 atoms the majority of which are carbon atoms and optionally containing a cyclic moiety of at least 5 atoms, prior to contact of the skin with the allergenic agent. The protective agent may be combined in a pharmacologically acceptable base for application to the skin.

Abstract: A method of inhibiting or reducing the irritation of skin resulting from allergic contact dermatitis, caused by contact with natural or synthetic allergenic agents, e.g. poison ivy, and dinitrochlorobenzene, respectively, is described. The method comprises applying to the skin an irritating reducing effective amount of a protective agent which is an organic compound having at least two polar groups, e.g. carboxyl groups, separated by a chain of at least 15 atoms the majority of which are carbon atoms and optionally containing a cyclic moiety of at least 5 atoms, prior to contact of the skin with the allergenic agent. The protective agent may be combined in a pharmacologically acceptable base for application to the skin.

Abstract: A method of inhibiting or reducing the irritation of skin resulting from allergic contact dermatitis, caused by contact with natural or synthetic allergenic agents, e.g. poison ivy, and dinitrochlorobenzene, respectively, is described. The method comprises applying to the skin an irritating reducing effective amount of a protective agent which is an organic compound having at least two polar groups, e.g. carboxyl groups, separated by a chain of at least 15 atoms the majority of which are carbon atoms and optionally containing a cyclic moiety of at least 5 atoms, prior to contact of the skin with the allergenic agent. The protective agent may be combined in a pharmacologically acceptable base for application to the skin.

Abstract: A method of inhibiting or reducing the irritation of skin resulting from allergic contact dermatitis, caused by contact with natural or synthetic allergenic agents, e.g. poison ivy, and dinitrochlorobenzene, respectively, is described. The method comprises applying to the skin an irritating reducing effective amount of a protective agent which is an organic compound having at least two polar groups, e.g. carboxyl groups, separated by a chain of at least 15 atoms the majority of which are carbon atoms and optionally containing a cyclic moiety of at least 5 atoms, prior to contact of the skin with the allergenic agent. The protective agent may be combined in a pharmacologically acceptable base for application to the skin.

Abstract: Compositions effective for protecting the skin from dermatologic irritation are formed by incorporating a protective agent which is an organic compound containing two or more polar groups, e.g. carboxyl groups, which are separated by at least 15 atoms the majority of which are carbon atoms and preferably containing a cyclic moiety of at least 5 atoms, e.g. the dimer of linoleic acid, in a pharmaceutically acceptable base.

Abstract: The hair is protected from damage by chemical agents, e.g. in bleaching, by either pretreatment with, or concurrent use of a protective agent and the damaging chemical. The protective agents disclosed are organic compounds containing two or more polar groups, e.g. carboxyl groups, which are separated by at least 15 atoms the majority of which are carbon atoms and preferably containing a cyclic moiety of at least 5 atoms, e.g. the dimer of linoleic acid.

Abstract: Compositions effective for protecting the skin from dermatologic irritation are formed by incorporating a protective agent which is an organic compound containing two or more polar groups, e.g. carboxyl group, which are separated by at least 15 atoms the majority of which are carbon atoms and preferably containing a cyclic moiety of at least 5 atoms, e.g. the dimer of linoleic acid, in a pharmaceutically acceptable base.